Farther Finance Advisors LLC Trims Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Farther Finance Advisors LLC decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 16.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 340 shares of the medical research company’s stock after selling 67 shares during the quarter. Farther Finance Advisors LLC’s holdings in IQVIA were worth $67,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Avior Wealth Management LLC boosted its stake in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the last quarter. Synergy Asset Management LLC purchased a new stake in IQVIA in the 4th quarter worth approximately $33,000. Versant Capital Management Inc lifted its holdings in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of IQVIA in the fourth quarter worth approximately $60,000. Finally, UMB Bank n.a. lifted its stake in shares of IQVIA by 72.8% during the 4th quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock valued at $79,000 after buying an additional 169 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.9 %

Shares of NYSE:IQV opened at $185.85 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business has a 50 day simple moving average of $194.94 and a two-hundred day simple moving average of $208.45. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $254.54. The firm has a market capitalization of $32.77 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Bank of America reduced their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Finally, Citigroup dropped their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.